Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03321630
Title A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
NYU Langone Health Recruiting New York New York 10016 United States Details
The Mount Sinai Hospital Recruiting New York New York 10029 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field